The impact of Cannabidiol on the frequency of convulsive seizures in patients with Dravet Syndrome compared to the use of Clobazam: A systematic review
DOI:
https://doi.org/10.33448/rsd-v13i10.47076Keywords:
Epilepsy, Cannabidiol, Clobazam.Abstract
Dravet Syndrome (DS) is an epileptic encephalopathy that presents itself as drug-resistant, commonly diagnosed in childhood, that is the reason for issues in cognition and child development. On account of being a drug-resistant illness, alternative options and treatment for adjuvant therapy have been suggested as an alternative with the aim of a better seizure management and quality of life for the patient. The present systematic review, aims to evaluate the efficacy of Cannabidiol in comparison with Clobazam on the reduction in seizure frequency in patients diagnosed with DS. Therefore, in a cautious analysis of the articles related to Dravet Syndrome, Cannabidiol and Cloazam, published in the PUBMED database, between 2019 and 2024, 9 articles were selected. Upon the data, it was possible to assess that both Cannabidiol and Clobazam were effective as adjuvants in treatment of Dravet Syndrome, which is drug-resistant, in addition to demonstrating acceptable tolerability and toxicity, even though it has greater adverse effects with the adjuvant treatment.
Downloads
References
Aderinto, N., Olatunji, G., Kokori, E., Ajayi, Y. I., Akinmoju, O., Ayedun, A. S., Ayoola, O. I., & Aderinto, N. O. (2024). The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: A narrative review of clinical trials. European Journal of Medical Research, 29(1), 182.
Brunklaus, A., & Zuberi, S. M. (2014). Dravet syndrome--from epileptic encephalopathy to channelopathy. Epilepsia, 55(7), 979–984.
Chen S, Li M, Huang M. Vagus nerve stimulation for the therapy of Dravet syndrome: a systematic review and meta-analysis. Front Neurol. 2024;15:1402989.
Chilcott, E., Díaz, J. A., Bertram, C., Berti, M., & Karda, R. (2022). Genetic therapeutic advancements for Dravet syndrome. Epilepsy & Behavior, 132, 108741.
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., & Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802.
Devinsky, O., Thiele, E. A., Wright, S., Checketts, D., Morrison, G., Dunayevich, E., & Knappertz, V. (2020). Cannabidiol efficacy independent of clobazam: meta‐analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 142(6), 531-540.
Ding, J., Li, X., Tian, H., Wang, L., Guo, B., Wang, Y., Li, W., Wang, F., & Sun, T. (2021). SCN1A mutation-beyond Dravet syndrome: A systematic review and narrative synthesis. Frontiers in Neurology, 12, 743726.
Gunning, B., Mazurkiewicz-Bełdzińska, M., Chin, R. F. M., Bhathal, H., Nortvedt, C., Dunayevich, E., & Checketts, D. (2021). Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta neurologica Scandinavica, 143(2), 154–163.
Klotz, K. A., Grob, D., Schönberger, J., Nakamura, L., Metternich, B., Schulze-Bonhage, A., & Jacobs, J. (2021). Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: A prospective open-label study. CNS Drugs, 35(11), 1207–1215.
Lattanzi, S., Trinka, E., Striano, P., Rocchi, C., Salvemini, S., Silvestrini, M., & Brigo, F. (2021). Highly purified cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome. CNS Drugs, 35(3), 265–281.
Lattanzi, S., Trinka, E., Russo, E., Del Giovane, C., Matricardi, S., Meletti, S., Striano, P., Damavandi, P. T., Silvestrini, M., & Brigo, F. (2023). Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Drugs, 83(15), 1409–1424.
Laux, L. C., Bebin, E. M., Checketts, D., Chez, M., Flamini, R., Marsh, E. D., Miller, I., Nichol, K., Park, Y., Segal, E., Seltzer, L., Szaflarski, J. P., Thiele, E. A., Weinstock, A., & CBD EAP Study Group. (2019). Long-term safety and efficacy of cannabidiol in children and adults with treatment-resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Research, 154, 13–20.
Miller, I., Scheffer, I. E., Gunning, B., Sanchez-Carpintero, R., Gil-Nagel, A., Perry, M. S., Saneto, R. P., Checketts, D., Dunayevich, E., Knappertz, V., & GWPCARE2 Study Group. (2020). Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial. JAMA Neurology, 77(5), 613–621.
Sampaio, R. F., & Mancini, M. C. (2007). Estudos de revisão sistemática: Um guia para síntese criteriosa da evidência científica. Revista Brasileira de Fisioterapia, 11(1), 83–89.
Scheffer, I. E., Halford, J. J., Miller, I., Nabbout, R., Sanchez-Carpintero, R., Shiloh-Malawsky, Y., et al. (2021). Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia, 62, 2505–2517.
Silvinato, A., Floriano, I., & Bernardo, W. M. (2022). Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associação Médica Brasileira (1992), 68(10), 1345–1357.
Strzelczyk, A., Lagae, L., Wilmshurst, J. M., Brunklaus, A., Striano, P., Rosenow, F., & Schubert‐Bast, S. (2023). Dravet syndrome: A systematic literature review of the illness burden. Epilepsia Open, 8(4), 1256-1270.
Wallace, A., Wirrell, E., & Kenney-Jung, D. L. (2016). Pharmacotherapy for Dravet syndrome. Pediatric Drugs, 18, 197–208.
Wirrell, E. C., Hood, V., Knupp, K. G., Meskis, M. A., Nabbout, R., Scheffer, I. E., Wilmshurst, J., & Sullivan, J. (2022). International consensus on diagnosis and management of Dravet syndrome. Epilepsia, 63(7), 1761–1777.
Wu, J., Zhang, L., Zhou, X., Wang, J., Zheng, X., Hu, H., & Wu, D. (2022). Efficacy and safety of adjunctive antiseizure medications for Dravet syndrome: A systematic review and network meta-analysis. Frontiers in Pharmacology, 13, 980937.
Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006). Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nature neuroscience, 9(9), 1142–1149.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Maria Gabriela Lemos Coelho de Araújo; Julia Sbizera Perez ; Marina Melo Aragão; Gabriela Carneiro Leão de Azevedo; Luis Gustavo Souza Mendes Lopes; Rebeca Gomes Brandão; Wagner Gonçalves Horta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
